share_log

石藥集團：石藥創新製藥股份有限公司截至2024年6月30日止6個月之未經審計財務資料

CSPC PHARMA: UNAUDITED FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE SIX MONTHS ENDED 30 JUNE 2024

HKEX ·  Aug 16 18:27

Summary by Futu AI

石藥集團旗下附屬公司石藥創新製藥股份有限公司於2024年8月16日發佈了截至2024年6月30日止6個月的未經審計中期報告。報告顯示，石藥創新的營業收入較上年同期下降27.71%，歸屬於上市公司股東的淨利潤下降48.27%，而扣除非經常性損益的淨利潤下降65.87%。此外，經營活動產生的現金流量淨額大幅下降277.60%。基本每股收益和稀釋每股收益均下降47.37%，加權平均淨資產收益率下降3.29%。總資產和歸屬於上市公司股東的淨資產分別下降21.23%和26.05%。財務報告指出，貨幣資金的大幅減少主要是由於巨石生物支付研發款項、公司購買大額存單、年度權益分派及股份回購所致。石藥集團提醒股東及投資者，該中期報告所載財務資料僅代表石藥創新的財務狀況，並非石藥集團整體的財務資料。
石藥集團旗下附屬公司石藥創新製藥股份有限公司於2024年8月16日發佈了截至2024年6月30日止6個月的未經審計中期報告。報告顯示，石藥創新的營業收入較上年同期下降27.71%，歸屬於上市公司股東的淨利潤下降48.27%，而扣除非經常性損益的淨利潤下降65.87%。此外，經營活動產生的現金流量淨額大幅下降277.60%。基本每股收益和稀釋每股收益均下降47.37%，加權平均淨資產收益率下降3.29%。總資產和歸屬於上市公司股東的淨資產分別下降21.23%和26.05%。財務報告指出，貨幣資金的大幅減少主要是由於巨石生物支付研發款項、公司購買大額存單、年度權益分派及股份回購所致。石藥集團提醒股東及投資者，該中期報告所載財務資料僅代表石藥創新的財務狀況，並非石藥集團整體的財務資料。
CSPC Pharma, a subsidiary of CSPC Pharma Group, released an unaudited interim report for the six months ended June 30, 2024 on August 16, 2024. According to the report, CSPC Pharma's revenue decreased by 27.71% compared to the same period last year, while the net profit attributable to shareholders of the listed company decreased by 48.27%, and the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses decreased by 65.87%. In addition, the net cash flow generated from operating activities decreased significantly by 277.60%. Basic earnings per share and diluted earnings per share both decreased by 47.37%, and the weighted average return on net assets decreased by 3.29%. Total assets and net assets attributable to shareholders of the listed company decreased by...Show More
CSPC Pharma, a subsidiary of CSPC Pharma Group, released an unaudited interim report for the six months ended June 30, 2024 on August 16, 2024. According to the report, CSPC Pharma's revenue decreased by 27.71% compared to the same period last year, while the net profit attributable to shareholders of the listed company decreased by 48.27%, and the net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses decreased by 65.87%. In addition, the net cash flow generated from operating activities decreased significantly by 277.60%. Basic earnings per share and diluted earnings per share both decreased by 47.37%, and the weighted average return on net assets decreased by 3.29%. Total assets and net assets attributable to shareholders of the listed company decreased by 21.23% and 26.05%, respectively. The financial report points out that the significant reduction in monetary funds is mainly due to the payment of R&D fees by CSPC Biotech, the purchase of large certificates of deposit by the company, the annual equity dividend, and stock repurchases. CSPC Pharma reminds shareholders and investors that the financial data included in this interim report only represents the financial condition of CSPC Pharma, not the entire CSPC Pharma Group.

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated